In the same way, there no significant difference in ROS level and ALDH1A1/2 activity between the different AML subgroups of interest such as Del17p and/or TP53‐mutated AML or NPM‐1‐mutated AML with the other AML (non‐specific) at diagnosis (Figure S2A,B). Here, TP53 is linked to acute myeloid leukemia.